Green Card Asset Management Analyst Jobs
Asset Management Analyst roles qualify for employment-based green card sponsorship under EB-2 or EB-3, depending on your degree level and the employer's filing strategy. Sponsorship typically follows the PERM labor certification process, where your employer documents that no qualified U.S. worker is available for the role before petitioning USCIS for permanent residency.
Find Green Card Asset Management Analyst JobsOverview
Showing 5 of 427+ Asset Management Analyst jobs
See all 427+ Asset Management Analyst Jobs
Sign up for free to unlock all listings, filter by visa type, and get alerts for new Asset Management Analyst roles.
Get Access To All JobsCompany Overview:
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology & oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Prime Medicine is a clinical-stage biotechnology company pioneering Prime Editing, a novel and precise "search-and-replace" gene editing technology capable of correcting the vast majority of disease-causing genetic mutations. Our approach allows us to make virtually any type of genetic edit — insertions, deletions, and all base-to-base conversions — without introducing double-strand breaks or requiring a separate donor DNA template. We are advancing a broad pipeline of Prime Editing–based therapies, including in vivo liver-directed programs and ex vivo approaches for ultra-rare disease, with a mission to develop one-time, curative genetic therapies for patients with limited or no treatment options today.
Position Overview
Location: Cambridge, MA (hybrid — min. 3-days a week onsite)
Reports to: VP, Programs and Strategy
Level: VP
Prime Medicine is seeking an experienced, strategic, and operationally rigorous Development Asset Leader to assume leadership of our in vivo LNP-delivered liver programs as they advance from early clinical development through licensure, beginning with our Wilson's Disease and Alpha-1 Antitrypsin Deficiency programs. The Asset Leader will step in seamlessly once a liver program has cleared IND and owns the asset through clinical PoC and regulatory approval/licensure. As Prime's liver portfolio grows, this leader is expected to scale from single-asset ownership into a franchise-level leadership capability, building the processes, governance, and team structure to efficiently deploy our capital to advance multiple concurrent clinical assets. The ideal candidate is equally comfortable engaging with both internal (executive management and Board) and external (regulatory authorities, KOLs, CRO/CDMO leadership) stakeholders as they are running a cohesive cross-functional team, building genuine esprit de corps across a lean organization while holding the asset accountable to timeline, budget, and scientific rigor.
Primary Responsibilities
- Own the Integrated Development Plan for liver assets from IND acceptance through regulatory approval/licensure, including trial design input, data package strategy, and key go/no-go decision points
- Anticipate, frame, and escalate the critical considerations that materially change the asset's risk/value profile to executive management
- Lead a matrixed team spanning Clinical, Regulatory, CMC/Manufacturing, Biostatistics, Pharmacovigilance, Med Affairs/Patient Advocacy, and Commercial
- Deploy, where appropriate, AI-enabled project management tooling (timelines, risk registers, cross-functional dashboarding)
- As the liver franchise expands, help design the team structure, governance cadence, and knowledge-transfer processes to advance Prime’s portfolio
- Serve as a key point of contact with CROs/CDMOs, KOLs, and patient advocacy groups for the asset, and represent the asset in regulatory interactions alongside Regulatory Affairs
Preferred Qualifications
- Advanced degree in life sciences, medicine, or related field (PhD, MD, PharmD) preferred; equivalent industry experience considered
- 12+ years of drug development experience in biotech/pharma, with demonstrated leadership of a clinical-stage asset from IND through late-stage development
- Direct experience in genetic medicines (gene/gene editing therapies, RNA-based therapeutics) or rare disease preferred; liver-directed or LNP delivery experience a strong plus
- Track record of cross-functional program leadership and accountability spanning Clinical, Regulatory, CMC, and Nonclinical
- Demonstrated ability to influence without formal authority, build team culture, and manage external partners (consultants, CROs, KOLs) as an extension of the internal team
- Experience or genuine interest in applying AI tools to project/portfolio management
- Comfort operating in a lean, resource-constrained organization where the Asset Leader is expected to build capability
The pay range reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on several factors including, but not limited to, relevant experience, skills, and education. This role is eligible for an annual short-term incentive award (e.g., bonus) and an annual long-term incentive award (e.g., equity). Prime Medicine offers a comprehensive Total Rewards package with robust health, financial, and wellness benefits—including medical, dental, vision, life insurance, a 401(k) match, and equity programs—along with generous paid time off, wellness days, and company-wide recharge breaks. Our commitment to employee well-being reflects our belief that when we care for our people, we strengthen our ability to put patients first and make meaningful impact together.
U.S. Pay Range $360,000—$408,000 USD
Prime Medicine is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, age, sexual orientation, gender identity, disability, veteran status, or any other classification protected by law.
Company Overview:
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is leveraging its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated, one-time, potentially curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology & oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Prime Medicine is a clinical-stage biotechnology company pioneering Prime Editing, a novel and precise "search-and-replace" gene editing technology capable of correcting the vast majority of disease-causing genetic mutations. Our approach allows us to make virtually any type of genetic edit — insertions, deletions, and all base-to-base conversions — without introducing double-strand breaks or requiring a separate donor DNA template. We are advancing a broad pipeline of Prime Editing–based therapies, including in vivo liver-directed programs and ex vivo approaches for ultra-rare disease, with a mission to develop one-time, curative genetic therapies for patients with limited or no treatment options today.
Position Overview
Location: Cambridge, MA (hybrid — min. 3-days a week onsite)
Reports to: VP, Programs and Strategy
Level: VP
Prime Medicine is seeking an experienced, strategic, and operationally rigorous Development Asset Leader to assume leadership of our in vivo LNP-delivered liver programs as they advance from early clinical development through licensure, beginning with our Wilson's Disease and Alpha-1 Antitrypsin Deficiency programs. The Asset Leader will step in seamlessly once a liver program has cleared IND and owns the asset through clinical PoC and regulatory approval/licensure. As Prime's liver portfolio grows, this leader is expected to scale from single-asset ownership into a franchise-level leadership capability, building the processes, governance, and team structure to efficiently deploy our capital to advance multiple concurrent clinical assets. The ideal candidate is equally comfortable engaging with both internal (executive management and Board) and external (regulatory authorities, KOLs, CRO/CDMO leadership) stakeholders as they are running a cohesive cross-functional team, building genuine esprit de corps across a lean organization while holding the asset accountable to timeline, budget, and scientific rigor.
Primary Responsibilities
- Own the Integrated Development Plan for liver assets from IND acceptance through regulatory approval/licensure, including trial design input, data package strategy, and key go/no-go decision points
- Anticipate, frame, and escalate the critical considerations that materially change the asset's risk/value profile to executive management
- Lead a matrixed team spanning Clinical, Regulatory, CMC/Manufacturing, Biostatistics, Pharmacovigilance, Med Affairs/Patient Advocacy, and Commercial
- Deploy, where appropriate, AI-enabled project management tooling (timelines, risk registers, cross-functional dashboarding)
- As the liver franchise expands, help design the team structure, governance cadence, and knowledge-transfer processes to advance Prime’s portfolio
- Serve as a key point of contact with CROs/CDMOs, KOLs, and patient advocacy groups for the asset, and represent the asset in regulatory interactions alongside Regulatory Affairs
Preferred Qualifications
- Advanced degree in life sciences, medicine, or related field (PhD, MD, PharmD) preferred; equivalent industry experience considered
- 12+ years of drug development experience in biotech/pharma, with demonstrated leadership of a clinical-stage asset from IND through late-stage development
- Direct experience in genetic medicines (gene/gene editing therapies, RNA-based therapeutics) or rare disease preferred; liver-directed or LNP delivery experience a strong plus
- Track record of cross-functional program leadership and accountability spanning Clinical, Regulatory, CMC, and Nonclinical
- Demonstrated ability to influence without formal authority, build team culture, and manage external partners (consultants, CROs, KOLs) as an extension of the internal team
- Experience or genuine interest in applying AI tools to project/portfolio management
- Comfort operating in a lean, resource-constrained organization where the Asset Leader is expected to build capability
The pay range reflects the full-time base salary range we expect to pay for this role at the time of posting. Base pay will be determined based on several factors including, but not limited to, relevant experience, skills, and education. This role is eligible for an annual short-term incentive award (e.g., bonus) and an annual long-term incentive award (e.g., equity). Prime Medicine offers a comprehensive Total Rewards package with robust health, financial, and wellness benefits—including medical, dental, vision, life insurance, a 401(k) match, and equity programs—along with generous paid time off, wellness days, and company-wide recharge breaks. Our commitment to employee well-being reflects our belief that when we care for our people, we strengthen our ability to put patients first and make meaningful impact together.
U.S. Pay Range $360,000—$408,000 USD
Prime Medicine is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, national origin, age, sexual orientation, gender identity, disability, veteran status, or any other classification protected by law.
See all 427+ Green Card Asset Management Analyst Jobs
Sign up for free to unlock all listings, filter by visa type, and get alerts for new Green Card Asset Management Analyst Jobs.
Get Access To All JobsTips for Finding Green Card Sponsorship as an Asset Management Analyst
Align your credentials to PERM's degree requirements
PERM certification locks in a minimum education and experience requirement for the role. Make sure your foreign degree evaluations are completed before your employer files, since PERM requires documented equivalency to a U.S. bachelor's or master's degree.
Target employers with active EB-3 filing history
Asset management firms that have sponsored analysts before understand the PERM recruitment obligations. Use Migrate Mate to filter roles by employers with green card filing activity, so you're not educating a hiring manager on the process from scratch.
Verify your SOC code before the employer files
Asset Management Analysts typically map to a specific Standard Occupational Classification code that determines your prevailing wage obligation under PERM. Review the O*NET occupation profile for your role and confirm the DOL wage level your employer intends to certify before the LCA is submitted.
Negotiate a job offer before your employer starts PERM
PERM is filed for a specific position, not a person. Your offer letter must match the job duties and minimum requirements on the PERM application. Mismatches between your offer and the labor certification can cause USCIS to deny the I-140 petition later.
Check your country's EB-3 priority date backlog early
Most nationalities face no meaningful wait for EB-3 green cards, but applicants born in India and China face multi-year backlogs. Knowing your priority date situation before accepting an offer helps you evaluate whether EB-2 with a National Interest Waiver self-petition is a faster parallel path.
Use OFLC Wage Search to validate your prevailing wage tier
Employers must pay at least the DOL prevailing wage for your specific metro area and experience level. Run your own OFLC Wage Search lookup before interviews so you can identify whether an offer falls at Level I, II, III, or IV, which affects both your salary negotiation and PERM eligibility.
Green Card Asset Management Analyst: Frequently Asked Questions
Does an Asset Management Analyst role qualify for EB-2 or EB-3 sponsorship?
It depends on the employer's minimum requirements for the position. If the role requires a master's degree or a bachelor's plus five years of progressive experience, the employer can file under EB-2. Roles requiring only a bachelor's degree typically qualify under EB-3. Many employers file under EB-3 first because PERM processing is more straightforward, then upgrade to EB-2 once the employee's credentials are stronger.
How does green card sponsorship differ from H-1B sponsorship for this role?
H-1B visa gives you temporary work authorization for up to six years, is subject to an annual lottery, and must be renewed. Employment-based green card sponsorship through PERM and I-140 leads to permanent residency with no cap at the EB-3 level for most nationalities. The process takes longer, typically two to four years from PERM filing to green card approval, but the outcome is permanent status rather than temporary authorization.
What is the PERM labor certification process for Asset Management Analysts?
PERM requires your employer to conduct a DOL-mandated recruitment campaign to show no qualified U.S. worker applied for the position. The employer posts the job, documents all applicants and rejection reasons, then files the ETA Form 9089 with DOL. Analyst review at DOL currently averages several months. Once certified, the employer files an I-140 immigrant petition with USCIS to establish your priority date.
How do I find Asset Management Analyst employers who sponsor green cards?
Migrate Mate lets you search specifically for Asset Management Analyst roles at employers with verified green card filing history, so you're not applying blindly and hoping sponsorship is available. Filtering by employers who have completed PERM filings for similar roles saves significant time and connects you with hiring managers already familiar with the sponsorship process.
Can I switch employers after my PERM is approved but before I get my green card?
Yes, under AC21 portability rules, you can change employers once your I-485 adjustment of status application has been pending for 180 days or more, as long as the new role is in the same or similar occupational classification. For Asset Management Analysts, a move to a comparable analytical or portfolio role within financial services typically qualifies. Confirm the SOC code overlap with your immigration attorney before accepting a new offer.